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Abstract
The dysregulation of apoptosis contributes in a variety of ways to the malignant phenotype. It
is increasingly recognized that the alteration of pro-apoptotic and anti-apoptotic molecules
determines not only escape from mechanisms that control cell cycle and DNA damage, but
also endows the cancer cells with the capacity to survive in the presence of a metabolically
adverse milieu, to resist the attack of the immune system, to locally invade and survive
despite a lack of tissue anchorage, and to evade the otherwise lethal insults induced by
drugs and radiotherapy. A multitude of apoptosis mediators has been identified in the past
decade, and the roles of several of them in breast cancer have been delineated by studying
the clinical correlates of pathologically documented abnormalities. Using this information,
attempts are being made to correct the fundamental anomalies at the genetic level.
Fundamental to this end are the design of more efficient and selective gene transfer
systems, and the employment of complex interventions that are tailored to breast cancer and
that are aimed concomitantly towards different components of the redundant regulatory
pathways. The combination of such genetic modifications is most likely to be effective when
combined with conventional treatments, thus robustly activating several pro-apoptotic
pathways.
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Introduction
The highly orchestrated form of cell death known as apop-
tosis goes awry to some extent in most cancers. Increas-
ingly, a general theme in cancer pathophysiology is the
development of a defect in the function of pro-apoptotic
molecules, such as p53, that commonly prepare the cell
for apoptosis whenever cell proliferation or DNA damage
is induced; lack of these molecules therefore deprives the
cell of a critical safety mechanism [1]. Alternatively, a func-
tional excess of anti-apoptotic molecules, such as Bcl-2,
may also occur in tumors. In each case, the result is an
imbalance that favors the inappropriate survival of tumor
cells. The mechanisms involved and their components are
attractive therapeutic targets because the tumor cell is
totally dependent on them for its survival, and appears typ-
ically to have a higher sensitivity to the induction of apop-
tosis than normal tissues [1,2]. In addition, restoring or
enhancing the capacity to undergo apoptosis may, inhttp://breast-cancer-research.com/content/2/1/032
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some cases, be a crucial event that renders tumors sensi-
tive to classical anticancer agents, such as those used in
chemotherapy [3,4••] and radiotherapy [5,6]. The present
review discusses the most common genetic alterations
that alter apoptosis regulation in breast cancer, and the
initial gene-based approaches that have been explored to
overcome them with therapeutic intent.
Dysregulated apoptosis contributes to cancer
There is a multitude of critical steps during the pathogene-
sis of cancer in which avoidance of programmed cell
death assures the progression, and maintenance, of the
malignant phenotype (Fig. 1) [7,8•,9,10]. Early during
tumor progression, defects in apoptosis allow the survival
of the cancer cell despite the existence of DNA damage
and cell-cycle dysregulation. This severe breaking of a
basic DNA housekeeping action contributes to the
genetic instability that characterizes cancer, and thus initi-
ates and sustains a spiral of further and further genetic
aberrations that endow tumor cells with extraordinary
capacities and adaptability. In fact, a reduction in apopto-
sis has been observed in patients with both carcinomas
and ‘normal’ epithelium in the breast that is associated
with fibrocystic changes. This is in contrast with breasts
with benign fibroadenomas, which have normal levels of
apoptosis and are not associated with malignant transfor-
mation [11•]. Further evidence has been obtained in trans-
genic mice that express the oncogenic simian virus 40
(SV40) large T antigen. These animals show a dramatic
increase in apoptosis during the development of preneo-
plastic mammary lesions, which is associated with a signif-
icant elevation in expression of the pro-apoptotic Bax. In
double-transgenic mice that are engineered to additionally
carry a mutated bax, a marked reduction in apoptosis
occurs in the preneoplastic lesions and the animals show
a subsequent increase in the number, size, and rate of
growth of breast tumors [12•]. Thus, disruption of apoptosis
mediators clearly contributes to mammary tumor progression.
As the tumor mass grows, the demands for oxygen, basic
nutrients, and growth factors are increasingly unmet. This
imbalance, which would otherwise induce cell death, is
not translated into effective death signals by a disturbance
in the apoptotic machinery, however. Furthermore, the
accumulating mutations of the tumor cell give rise to new
cell surface mutated proteins, or epitopes. These potential
tumor antigens, however, do not usually generate a strong
immune response, or the response is not efficacious.
Such ‘sheltering’ from cytotoxic T lymphocytes (CTLs) and
other immune effectors has been associated with a variety
of changes in the control of apoptosis that effectively
protect the cancer cell from otherwise lethal insults medi-
ated by CTLs and other immune mediators [13].
Later in the natural history of malignant tumors, metas-
tases eventually develop, which determines in most cases
an ominous change in the prognosis of the disease. For
this event to occur the cell needs to acquire the capacity
Figure 1
Dysregulation of apoptosis contributes to the pathophysiology of cancer. A variety of defects in the apoptotic machinery contribute to avoidance of
apoptosis by tumor cells throughout the entire carcinogenic process. The enhanced capacity of tumor cells to survive allows them to overcome (in
analogy to decathlon athletes) numerous challenges encountered, not only in the primary tumor location, but also during their vascular distribution
and at their multiple final destinations. The universal dependence of tumor cells on mechanisms to avoid apoptosis suggests a ‘window of
homogeneity’ that could be exploited therapeutically. CTL, cytotoxic T lymphocyte.
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to disseminate and survive despite its lacking tissue
anchorage, which normally would induce a type of apopto-
sis called ‘anoikis’. Recently, the involvement of cellular
receptors of death signals in anoikis has been described
[14••], and the disturbance of these receptors and their
related transductional apparatus in cancer cells has been
suggested. Lastly, the tumor regression induced by
chemotherapy, radiotherapy, and hormone therapy
depends to a large extent on the induction of apoptosis
[7,15–17]. In breast cancer, the administration of
chemotherapy immediately before surgery has allowed
analysis of the induction of apoptosis in the remaining
tumor within the resected specimen. Interestingly, a posi-
tive correlation has been found between the apoptotic
index, the clinical response, and patient survival [18••].
Tumor cells frequently emerge, however, that resist the
apoptosis-inducing effects of those maneuvers, thus
essentially escaping from current therapeutic interventions
[19–21]. On aggregate, the consequences of dysregula-
tion of apoptosis are pervasive throughout the natural
history of cancer, and have been established as a univer-
sal component of the malignant phenotype.
Mechanisms of apoptosis avoidance in breast
cancer
In cancer, cellular proliferation goes on unchecked and
cellular death does not occur to the extent that it should,
despite several otherwise potent death stimuli being con-
spicuously present. These two aspects of tumor patho-
physiology have been analyzed in breast cancer, and
consistently found to be disturbed [22–24]. In fact,
expression levels of several cell growth regulators and
pro-apoptotic and anti-apoptotic proteins are usually per-
turbed in breast cancer, and their alteration has been
associated with prognosis and with the response to con-
ventional anticancer treatments (see below).
Growth factors and their receptors
Many growth factors and their receptors influence the
growth and proliferation of breast cancer cells [25]. Typi-
cally, normal versions of human epidermal growth factor
receptor-related gene (HER)-2/neu (c-erbB-2), epidermal
growth factor receptor (or c-erbB-1), and insulin-like
growth factor (IGF)-1 receptor are overexpressed. Inter-
estingly, the aberrant control of cell proliferation by growth
factor receptors is mechanistically related to an inhibition
of apoptosis. For instance, overexpression of HER-2
upregulates anti-apoptotic bcl-2 and bcl-xL, and thus
inhibits  in vitro tamoxifen-induced apoptosis [26]. A similar
effect of HER-2 has been found on taxol-induced apopto-
sis. As another example, IGF-1 protects breast cancer
cells from apoptosis that is induced by chemotherapeutic
drugs [27]. Thus, mechanisms known to alter tumor cell
proliferation may also directly contribute to the avoidance
of apoptosis in breast cancer cells. The relevant molecular
pathology, and the potential for modulating these mole-
cules in the context of gene therapy, has been reviewed
elsewhere [28,29].
Genes that regulate apoptosis
In addition to factors that are involved in controlling cell prolif-
eration, abnormalities have been identified in breast cancers
in many genes that regulate the apoptotic cascade, including
p53,  bcl-2,  bax, c-myc, p21WAF/CIP1, and many others
(Table 1). As a consequence, tumor cells express several
proteins that render them resistant to apoptosis. Blocking
cell death promotes neoplastic transformation [10].
p53
Mutations in the p53 gene are a common molecular
abnormality in breast cancer [30,31]. A consequence of
the lack of normal function of p53 may be the failure to
induce apoptosis in cells with damaged DNA [32], and it
can also possibly impair a full apoptotic response to the
administration of hormonal or chemotherapeutic interven-
tions. Furthermore, it can contribute to genomic instability
[33], and thus increase the probability of appearance of
additional mutations that are advantageous for survival of
the tumor cell. p53 stops the cell cycle and induces apop-
tosis through stimulation of p21WAF/CIP1, an inhibitor of
cyclin-dependent kinases. In effect, experimental over-
expression of p21WAF/CIP1 in human breast cancer cell
lines suppresses growth, and induces apoptosis [34].
Bcl-2 family
The genes of the bcl-2 family have emerged as key regula-
tors of apoptosis, and appear to be dysregulated in a
number of tumors, including breast cancers [23,35,36].
Several members of the Bcl-2 family, including bcl-2, Bcl-
XL, Mcl-1, and A1/Bfl-1, suppress apoptosis; whereas
others, including Bax, Bak, Bok/Mtd, Bad, Bik, Bid,
Bim/Bod, and HrK, induce apoptosis. The extent of apop-
tosis is inversely associated with Bcl-2 expression in pre-
malignant and malignant breast lesions [37–40].
Paradoxically, Bcl-2 expression correlates with favorable
clinicopathologic features, as well as with improved
disease-free and overall survival [41–47]. Furthermore,
patients with elevated Bcl-2 levels appear to derive the
greatest benefit from endocrine therapy [48–50]. Only in a
subset of well differentiated and progesterone receptor-
positive tumors has Bcl-2 been reported to enhance
disease progression [35]. As an explanation for the appar-
ent paradox of decreasing levels of anti-apoptotic Bcl-2
levels with increasing tumor grade, it has been proposed
that Bcl-2 has an early role within the tumor by rescuing
cells with otherwise lethal mutations. After additional
oncogene activation, some cells would acquire additional
ways to protect themselves against apoptosis [51]. At that
point, loss of Bcl-2 might confer a growth advantage. In
fact, Bcl-2 is known to restrain cell proliferation [10]. Thus,
expression of Bcl-2 would change from high levels in early
or low-grade tumors, characterized by low apoptotichttp://breast-cancer-research.com/content/2/1/032
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.indices, to low levels in advanced or high-grade tumors,
characterized by high apoptotic indices.
Bax
The levels of expression of Bax or the Bax:Bcl-2 ratio, as
determined by immunostaining, directly correlate in breast
tumors with longer patient survival [46,47] and/or better
response to therapy in some [52] but not all studies [53].
In this regard, bax is considered a tumor suppressor gene,
and is itself a direct transcriptional target of p53. Interest-
ingly, haploid loss of bax leads to accelerated mammary
tumor development in SV40 large T antigen double trans-
genic mice [12•], which suggest that the protective effect
of bax is dose-dependent. In addition, successful induc-
tion of apoptosis by chemotherapy and radiation is associ-
ated with augmented expression of Bax [54]. Furthermore,
induced overexpression of Bax renders tumor cells more
sensitive to drugs [55], whereas ablation of Bax reduces
drug-induced apoptosis [56]. Mechanistically, Bax pro-
motes cell death by directly binding and antagonizing pro-
survival Bcl-2 [57], and it also induces apoptosis by itself
through its direct channel-forming activity in mitochondria
and activation of caspase pathway [58•,59••]. The correla-
tions mentioned above and the described mechanism of
action of Bax demonstrates its importance not only as a
modulator of the response to treatments, but also as a
direct mediator of their cytotoxicity.
Caspases
Caspases are the essential effectors of apoptotic cell
death [60]. Disturbance of their activation is therefore an
obvious mechanism whereby breast cancer cells might
avoid apoptosis. Two distinct starting points for the activa-
tion of caspases have been characterized [10] as follows.
First, activation may originate at so-called death receptors.
The ligation of CD95 (Fas) or related members of the
tumor necrosis factor (TNF) receptor family leads to
assembly of a ‘death-inducing signaling complex’ at the
plasma membrane. Within the death-inducing signaling
complex, the adaptor protein fas-associating death
domain-containing protein/mediator of receptor induced
toxicity 1 (FADD/MORT1) recruits cytosolic caspase-8,
which promotes its autocatalytic activation and release
into the cytosol. This event leads to the subsequent activa-
tion of downstream caspases (ie caspase-3, -6 and -7),
which serve as the final effectors of apoptosis [61]. Addi-
tionally, the TNF/CD95 receptor pathway has been found
to activate apoptosis also via the mitochondria, which pos-
sibly allows the amplification of the pro-apoptotic signal. In
effect, caspase-8 can cleave cytosolic Bcl-2 homology
domain 3 interacting domain death agonist (BID), a pro-
apoptotic member of the Bcl-2 superfamily [62••,63]. The
truncated BID translocates into the mitochondria, where it
binds to Bax and leads to the release of cytochrome c into
the cytosol. Once released, cytochrome c combines with
apoptotic protease activating factor-1 and procaspase-9
in the complex termed apoptosome, leading to the forma-
tion of caspase-9, and to the subsequent activation of the
caspase cascade, including caspase-3. Binding to the
apoptosome of Bcl-2 or Bcl-XL can inhibit this effector
pathway. Of interest, Bcl-2 and Bcl-XL can also interfere
with the function of translocated BID [62••,64], thus block-
ing the mitochondria-dependent signaling arm that origi-
nates in the death receptors.
Second, apoptosis can be triggered by DNA damage and
independently of FADD/MORT1 and caspase-8, via a
similar mitochondrial step that culminates in the release of
cytochrome c from mitochondria into the cytosol. DNA
damage and other stimuli act through both p53-depen-
dent and -independent pathways that are actively being
characterized (for a summary see [20]).
In breast cancer, disturbance of death receptor pathways
may be important for several reasons. First, it may help to
avoid killing by CTLs, which usually act by expression of
CD95L (Fas ligand) to trigger apoptosis of target cells.
Second, it may conversely allow expression of CD95
ligand by tumor cells and thus determine the killing of acti-
vated lymphocytes, which usually express Fas. Finally,
expression of Fas ligand may contribute to invasiveness by
clearing stromal cells that express Fas. Recently, all of
these hypotheses have been elegantly confirmed in tumor
specimens from patients [65]. In effect, expression of Fas
ligand has been positively correlated and expression of
CD95 inversely correlated with the histopathologic grading
of the analyzed breast tumors. In addition, tumor-infiltrating
lymphocytes and stromal cells in close proximity to CD95L-
expressing breast cancer cells underwent apoptosis. Fur-
thermore, CD95+ target cells cultured on breast cancer
tissue sections underwent apoptosis, but could be rescued
when CD95 ligand was specifically blocked by a CD95-Fc
fusion molecule [65]. Thus, alterations in CD95/death
receptor signaling may allow breast tumor cells to avoid
apoptosis and also contributes to their escape from the
immune system and to their invasive phenotype.
Inhibitor of apoptosis proteins
The signaling pathways that promote apoptosis are exquis-
itely counterbalanced by several families of proteins, each
of which render the cell resistant to particular pro-apoptotic
stimuli and effectors. Not surprisingly, increased activity of
such protective proteins may result in aggressive tumor
growth and resistance to cytotoxic treatment [66]. In addi-
tion to anti-apoptotic Bcl-2 and analogs, other relevant pro-
teins are the inhibitor of apoptosis protein (IAP) family and
the heat shock proteins (HSPs). The IAP family members
directly bind and inhibit certain caspases [67,68]. Given
the central role of caspases in apoptosis, and the role of
apoptosis in the cytotoxicity of chemotherapy and radio-
therapy, it follows that IAPs protect tumor cells from several
Breast Cancer Research    Vol 2 No 1 Gómez-Navarro et al
36drugs and other therapies that induce apoptosis [68]. Infor-
mation about the expression of most IAP members in
human tumors, including breast cancer, is scarce. One
exception is the IAP named survivin, which is known to be
highly overexpressed in breast and most other cancers
[69••,70], thus supporting the concept that increased activ-
ity of IAPs contributes to breast tumorigenesis. Interest-
ingly, survivin may counteract a default induction of
apoptosis in G2/M phase [71]. Its overexpression may
therefore overcome an apoptosis-related cell cycle check-
point and favor aberrant progression of transformed cells
through mitosis. Of note, transcriptional activation of IAPs
is dependent on nuclear factor-kB (NF-kB). In turn, IAPs
can activate NF-kB and thus create a positive feedback
loop, enhancing survival signals. This loop may in part
explain the potent anti-apoptotic activity of NF-kB [66], and
also suggests a possible target for therapeutic intervention.
Heat shock proteins
HSPs are involved in cellular resistance to stress. They are
among the most conserved proteins in phylogeny, indicat-
ing their central role in supporting cell survival not only after
heat shock, but also most other apoptotic stimuli [66]. Clin-
icopathologic studies [72–75] have shown that expression
of HSP-70 occurs in high-grade tumors and correlates in
breast cancer with shorter disease-free survival, increased
cell proliferation, and poor differentiation, as well as lymph
node involvement. In addition, expression of HSP-70
inversely correlates with the response to combination
chemotherapy, radiotherapy, and hyperthermia, whereas no
correlation has been found with the response to tamoxifen
[75–77]. Interestingly, HSP-70 can rescue cells from
apoptosis induced by TNF, even after the activation of
effector caspases, which indicates that it has a markedly
downstream point of action in the apoptosis pathway and
is therefore a particularly attractive therapeutic target.
Gene therapeutics for modulation of apoptosis
The consequences of dysregulation of apoptosis on tumor
pathophysiology are extremely diverse (see above and
Fig. 1). The core machinery of cell death, however, seems
to be formed by a discreet number of protein families
(Fig. 2). Modulation of a limited number of targets by deliv-
ery of genes that encode apoptosis-related proteins would
therefore have multiple beneficial effects on the malignant
phenotype. Not only would tumor cell proliferation be
properly balanced by increased cell death, but also barri-
ers to the immune response would fall, tumor invasiveness
would be crippled, and sensitivity to the cytotoxicity
induced by drugs and radiation would be restored. Impor-
Figure 2
Regulation of cell death. Apoptosis involves a sensor that detects pro-apoptotic stimuli, a signal transduction network, and execution machinery.
Despite the complexity of its regulation, execution of programmed cell death is effected by the well-defined family of caspases. Upstream, at least
one family of proteins exist at each level of response to pro-apoptotic stimuli that is able to block a deadly signal, including the heat shock proteins
(HSPs), the anti-apoptotic death effector domain proteins (ADEDs), several members of the Bcl-2 family, the inhibitors of apoptosis proteins (IAPs),
and the nuclear factor-kB (NF-kB) family of transcription factors. Conversely, executioners of apoptosis such as Bax may be not functional,
inclining the balance towards inappropriate survival of the tumor cell. In breast cancer, many of these proteins are dysregulated. BID, Bcl-2
homology domain 3 interacting domain death agonist; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand.
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37tantly, the need that tumor cells have for mechanisms that
allow them to avoid apoptosis is universal, and shared by
all tumor localizations in the body. This avoidance repre-
sents a ‘window of homogeneity’ that can be targeted in
the context of the formidable tumor heterogeneity. With
the increasing recognition of the molecular basis of the
apoptotic pathway [1,60,78–80], and the description of
several of its components acting as oncogenes or tumor
suppressor genes, gene therapy has thus emerged as a
rational strategy for the modulation of apoptosis
[20,81–84]. The following is a brief summary of
approaches that have already been clinically explored in
the context of breast cancer. A discussion of the require-
ments for successful exploitation of the apoptotic machin-
ery using gene transfer and some of the solutions being
developed is then provided.
Clinically explored strategies
Preliminary attempts to explore the therapeutic modulation
of apoptosis against cancer by gene transfer have been
started, driven by encouraging preclinical data in animal
models. Clinical trials are currently ongoing to evaluate the
value of pro-apoptotic p53 and adenoviral E1A, and a
growing number of other candidate genes are being consid-
ered and tested preclinically (see [20,81,82] and Table 1).
Supplementation or restoration of p53
Direct induction of apoptosis has been attempted by replac-
ing the tumor suppressor gene p53. Several factors made
this gene an attractive candidate, including its frequent inac-
tivation in human tumors, the observed lack of toxicity of
wild-type  p53 itself, the control that it exerts in multiple other
genes implicated in apoptosis and cell cycle regulation, and
some experimental evidence for a bystander effect. Both in
vitro and in vivo animal studies [84–87] have indeed shown
induction of apoptosis and suppression of tumorigenicity in
human breast cancer models after p53 gene delivery via
recombinant adenoviral vectors. Of interest, this result has
also been observed in tumor cell sublines selected for resis-
tance to drugs that are commonly used in the treatment of
breast cancer [88] and in tumor cells expressing wild-type
p53 [89]. Furthermore, adenovirus-mediated delivery of p53
augments the cytotoxic effect of the chemotherapeutic drug
paclitaxel [90]. These preclinical studies were followed by
two clinical trials in breast cancer in which p53 is currently
being administered intralesionally, or incubated ex vivo with
bone marrow for purging of contaminating breast cancer
cells [91]. Potential obstacles for the successful clinical
exploitation of p53, however, have arisen with the observa-
tion that wild-type p53 can be inactivated in human breast
cancer cells that express mutant p53 [92], and with the low
efficiency in vivo of current gene delivery vectors.
Adenoviral E1A
In addition to restoration of p53, the other pro-apoptotic
approach currently being clinically tested is based on
liposome-mediated delivery of the adenoviral gene E1A
[91,93]. Gene transfer of E1A inhibits transcription of the
human HER-2/neu promoter, and suppresses the tumori-
genicity and metastatic potential of the HER-2/neu onco-
gene in cells that overexpress this oncogene [94]. An
analogous effect of E1A in anchorage-independent
growth and tumorigenicity has been shown in a HER-
2/neu-independent manner [95]. Finally, E1A sensitizes
mammalian cells to immune-mediated apoptosis in a p53-
independent manner [96]. Thus, delivery of E1A could
have an effect in vivo that exceeds the limitations imposed
by the heterogeneity in the HER-2/neu or p53 status
within the tumor.
Requirements for pro-apoptotic gene therapy
A variety of additional interventions and targets have been
proposed for the gene-based therapeutic induction of
apoptosis (see Table 1, and the references therein). Here,
comments are limited to theoretical aspects that need to
be considered for designing successful therapeutic inter-
ventions for breast cancer based on the genetic modula-
tion of apoptosis. Specifically, the gene transfer systems
and knowledge of the genetic pathophysiology of the
disease as the most critical aspects are considered.
High levels of gene transfer
Gene transfer vectors are needed that can trigger apopto-
sis in most malignant cells in any given tumor. Most fre-
quently, current vector systems have been employed for
delivery of therapeutic nucleic acids to relevant target cells
in loco-regional contexts. In general, a fundamental recog-
nition in most of these studies has been the disparity noted
between the in vitro and in vivo gene transfer efficiencies
of these vectors, with a generally suboptimal tumor trans-
duction [97]. For disseminated disease, employment of
available vectors is not presently feasible. This restriction is
based on their limited capacity to accomplish efficient gene
transfer to widely disseminated tumor targets in vivo.
Implicit in this limitation is the recognition of three require-
ments for any candidate vector system for this purpose: the
ability to accomplish highly efficient and nontoxic gene
delivery after direct in vivo delivery via the intravascular
route; the ability to accomplish targeted, specific gene
delivery to a selected cellular subset; and the ability to
escape the innate and adaptive immune responses.
With regard to the first requirement, only two presently
available vector systems, cationic liposomes and recombi-
nant adenoviral vectors, have been reported to transduce
various end organs after in vivo gene delivery [98–101].
However, low levels of gene expression [102,103], or
promiscuous tropism and entrapment of the vector by the
reticuloendothelial system, mostly in the liver [104],
respectively, have undermined the utility of the aforemen-
tioned vector systems for accomplishing transduction of
normal breast tissue and disseminated breast cancer
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second requirement (ie the evaluation of tissue-specific or
tumor-specific promoters for transcriptional targeting of
therapeutic genes in the context of in vivo models of
breast cancer) [105]. With regard to the effects of the
immune response, viral vectors display foreign antigens
that can induce a strong cellular and humoral immune
response in humans [106–108]. This can ultimately deter-
mine immune-mediated clearance of the vector and of the
virally infected target cells [109], and precludes efficient
readministration of the vector.
Thus, important limitations of current approaches used for
implementation of pro-apoptotic gene therapy for dissemi-
nated cancers, including breast cancer, have been noted.
Although many potentially effective strategies exist to
achieve the molecular treatment of breast cancer, gene
delivery issues have limited definitive evaluation of these
methods in clinically relevant models.
In this regard, understanding of the determinants of vector
efficacy at a cellular level has recently allowed vectors to be
designed that achieve cell-specific gene delivery in the loco-
regional context. For instance, altering the tropism of aden-
oviral vectors by bifunctional, antibody-based conjugates
and by genetic engineering of the binding sites of the virus
dramatically enhances the infectivity of otherwise refractory
tumor cells [110]. This occurs by allowing the cellular entry
of the virus through heterologous pathways, thus overcom-
ing the paucity of its receptor, coxsackie and adenovirus
receptor (CAR), which characterizes human primary tumors.
Here the mandate for a high level of gene transfer may be
stricter, given the lack of firm evidence for a useful
bystander effect mediated by pro-apoptotic interventions,
perhaps with the exception of replacement of p53 [111]. In
this case, a better definition of the basis of bystander effects
observed after gene delivery of p53 should lead to the
exploitation of similar schemas by designing ad hoc thera-
peutic payloads. Examples would be secretory molecules
such as the IGF binding protein 3 [112], which is induced
by p53 and inhibits the powerful growth factor IGF-1; and
translocating molecules, such as fusion proteins derived
from the herpes simplex virus protein VP22 [113] or from
the Tat protein of human immunodeficiency virus type 1
[114–117]. Further advances are also needed to under-
stand the determinants of the biodistribution of viral vector
after systemic intravascular administration. To this end,
novel molecular and imaging technologies [118] have been
developed that allow the amount of vector in relevant
tissues to be quantified [119] and gene expression to be
followed noninvasively in vivo [120•], both of which should
accelerate these fundamental studies.
High therapeutic index
Given the ubiquity of the numerous cellular proteins
involved in apoptotic pathways, highly selective activation
in cancer cells of lethal processes may also be a critical
requirement of therapeutic maneuvers. The lower thresh-
old for undergoing apoptosis that characterizes tumor
cells [1,2] could, however, offer an advantageous thera-
peutic window that makes this requirement less stringent.
Certain pro-apoptotic interventions might still require a
more stringent level of specificity. In such cases, vector
targeting could provide the required restriction in the
expression of the pro-apoptotic molecules.
Targeted gene therapy for breast cancer can be accom-
plished at different levels [121]. In one approach, the
tumor cell can be targeted at the level of transduction to
achieve the selective delivery of the therapeutic gene. This
involves the derivation of a vector that binds selectively to
the target breast cancer cell. Alternatively, the therapeutic
gene can be placed under the control of breast tumor-
specific transcriptional regulatory sequences that are acti-
vated in tumor cells, but not in normal cells, and therefore
target expression selectively to the tumor cell (for a review
see [28]). In addition, targeted gene therapy for cancer
can exploit the unique physiology of solid tumors, such as
hypoxia [122]. To date, targeted gene therapy has been
attempted by employing either transductional targeting or
transcriptional targeting alone. Again, enhancement of the
overall level of specificity by combining the complementary
approaches of transductional and transcriptional targeting
may be required, each of which might be imperfect or
‘leaky’ by itself [121]. Perhaps more importantly, vector
targeting may confer, in addition to selectivity, a signifi-
cantly higher level of gene transfer, as mentioned above.
Multiple interventions and modalities
The signaling circuits that control apoptosis are complex
and redundant, and tumors are formidably heterogeneous.
Therefore, concomitant modulation of several components
of the apoptotic pathways may be needed to provoke cell
death in a robust and consistent manner. In this regard,
the complex phenotype of the caspase knockout mice
revealed that multiple and redundant mechanisms of
caspase activation operate in parallel [123]. Recent high-
throughput studies (for instance employing complemen-
tary DNA microarrays and serial analysis of gene
expression) allow identification of patterns of gene expres-
sion and their variation under appropriate stimuli, which
will contribute to the dissection of the relevant pathways in
breast cancer [124••,125]. Interventions downstream in
the circuits might also be preferable for avoiding regula-
tory counterbalances that may dissipate the effect of the
intervention. For instance, multiple genes act downstream
of p53 that alter the response to p53 restoration. In con-
trast, Bax has a more downstream role in effecting apopto-
sis, which perhaps explains its more predictable
cytotoxicity on tumor cells [126••]. Finally, the magnitude
of cell death after most pro-apoptotic interventions in vitro
is cell line-dependent, with some tumor cells typically
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has prompted the evaluation of combining a variety of pro-
apoptotic interventions, and their association with
chemotherapy [4••], radiotherapy [6,127], and other bio-
logicals [128]. These multimodality treatments have con-
sistently showed that higher levels of cell death are
obtained when different pathways are modulated and
modalities are combined, clearly indicating that the tar-
geted pathways do not totally overlap.
Conclusion
The contribution of a dysregulation of apoptosis to the
malignant phenotype is increasingly being recognized. In
that context, novel technologies for high throughput analy-
sis of the expression profile of breast tissues, normal and
malignant, under a variety of experimental and treatment
conditions, are becoming widespread. The information thus
collected will allow the apoptotic machinery and its dys-
function to be defined with extraordinary breadth and preci-
sion. At the same time, more efficient and selective gene
transfer systems are being designed, which will allow the
implementation of complex genetic interventions tailored to
breast cancer and aimed at different components of the
redundant regulatory pathways. The combination of such
genetic modifications is most likely to be effective when
combined with conventional treatments, thus robustly acti-
vating several pro-apoptotic pathways, and paving the way
for the therapeutically beneficial application of pro-apop-
totic gene therapy for cancer of the breast.
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